-
Something wrong with this record ?
Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L
AS. Ashhurst, AH. Tang, P. Fajtová, MC. Yoon, A. Aggarwal, MJ. Bedding, A. Stoye, L. Beretta, D. Pwee, A. Drelich, D. Skinner, L. Li, TD. Meek, JH. McKerrow, V. Hook, CT. Tseng, M. Larance, S. Turville, WH. Gerwick, AJ. O'Donoghue, RJ. Payne
Language English Country United States
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
U01 TW006634
FIC NIH HHS - United States
- MeSH
- Antiviral Agents chemical synthesis chemistry pharmacology MeSH
- Biological Products chemical synthesis chemistry pharmacology MeSH
- A549 Cells MeSH
- Chlorocebus aethiops MeSH
- COVID-19 metabolism MeSH
- COVID-19 Drug Treatment MeSH
- Cysteine Proteinase Inhibitors chemical synthesis chemistry pharmacology MeSH
- Cathepsin L antagonists & inhibitors metabolism MeSH
- Antimicrobial Cationic Peptides chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Microbial Sensitivity Tests MeSH
- Molecular Conformation MeSH
- Proteomics MeSH
- SARS-CoV-2 drug effects MeSH
- Vero Cells MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a promising drug target for novel antivirals against SARS-CoV-2. The marine natural product gallinamide A and several synthetic analogues were identified as potent inhibitors of cathepsin L with IC50 values in the picomolar range. Lead molecules possessed selectivity over other cathepsins and alternative host proteases involved in viral entry. Gallinamide A directly interacted with cathepsin L in cells and, together with two lead analogues, potently inhibited SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range. Reduced antiviral activity was observed in cells overexpressing transmembrane protease, serine 2 (TMPRSS2); however, a synergistic improvement in antiviral activity was achieved when combined with a TMPRSS2 inhibitor. These data highlight the potential of cathepsin L as a COVID-19 drug target as well as the likely need to inhibit multiple routes of viral entry to achieve efficacy.
Kirby Institute University of New South Wales Sydney NSW2052 Australia
School of Chemistry The University of Sydney Sydney NSW2006 Australia
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010939
- 003
- CZ-PrNML
- 005
- 20220506130538.0
- 007
- ta
- 008
- 220425s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.1c01494 $2 doi
- 035 __
- $a (PubMed)34730959
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ashhurst, Anneliese S $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia $u School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW2006, Australia
- 245 10
- $a Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L / $c AS. Ashhurst, AH. Tang, P. Fajtová, MC. Yoon, A. Aggarwal, MJ. Bedding, A. Stoye, L. Beretta, D. Pwee, A. Drelich, D. Skinner, L. Li, TD. Meek, JH. McKerrow, V. Hook, CT. Tseng, M. Larance, S. Turville, WH. Gerwick, AJ. O'Donoghue, RJ. Payne
- 520 9_
- $a Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a promising drug target for novel antivirals against SARS-CoV-2. The marine natural product gallinamide A and several synthetic analogues were identified as potent inhibitors of cathepsin L with IC50 values in the picomolar range. Lead molecules possessed selectivity over other cathepsins and alternative host proteases involved in viral entry. Gallinamide A directly interacted with cathepsin L in cells and, together with two lead analogues, potently inhibited SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range. Reduced antiviral activity was observed in cells overexpressing transmembrane protease, serine 2 (TMPRSS2); however, a synergistic improvement in antiviral activity was achieved when combined with a TMPRSS2 inhibitor. These data highlight the potential of cathepsin L as a COVID-19 drug target as well as the likely need to inhibit multiple routes of viral entry to achieve efficacy.
- 650 _2
- $a buňky A549 $7 D000072283
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kationické antimikrobiální peptidy $x chemická syntéza $x chemie $x farmakologie $7 D023181
- 650 _2
- $a antivirové látky $x chemická syntéza $x chemie $x farmakologie $7 D000998
- 650 _2
- $a biologické přípravky $x chemická syntéza $x chemie $x farmakologie $7 D001688
- 650 _2
- $a COVID-19 $x metabolismus $7 D000086382
- 650 _2
- $a kathepsin L $x antagonisté a inhibitory $x metabolismus $7 D056668
- 650 _2
- $a Cercopithecus aethiops $7 D002522
- 650 _2
- $a inhibitory cysteinových proteinas $x chemická syntéza $x chemie $x farmakologie $7 D015853
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a molekulární konformace $7 D008968
- 650 _2
- $a proteomika $7 D040901
- 650 _2
- $a SARS-CoV-2 $x účinky léků $7 D000086402
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a Vero buňky $7 D014709
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Tang, Arthur H $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia
- 700 1_
- $a Fajtová, Pavla $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 16610Prague, Czech Republic
- 700 1_
- $a Yoon, Michael C $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States $1 https://orcid.org/0000000229005257
- 700 1_
- $a Aggarwal, Anupriya $u Kirby Institute, University of New South Wales, Sydney, NSW2052, Australia
- 700 1_
- $a Bedding, Max J $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia
- 700 1_
- $a Stoye, Alexander $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia
- 700 1_
- $a Beretta, Laura $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
- 700 1_
- $a Pwee, Dustin $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
- 700 1_
- $a Drelich, Aleksandra $u Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas77755-1001, United States
- 700 1_
- $a Skinner, Danielle $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
- 700 1_
- $a Li, Linfeng $u Department of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas77843, United States $1 https://orcid.org/0000000161854999
- 700 1_
- $a Meek, Thomas D $u Department of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas77843, United States $1 https://orcid.org/0000000219318073
- 700 1_
- $a McKerrow, James H $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
- 700 1_
- $a Hook, Vivian $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
- 700 1_
- $a Tseng, Chien-Te $u Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas77755-1001, United States
- 700 1_
- $a Larance, Mark $u Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW2006, Australia $1 https://orcid.org/0000000285792267
- 700 1_
- $a Turville, Stuart $u Kirby Institute, University of New South Wales, Sydney, NSW2052, Australia
- 700 1_
- $a Gerwick, William H $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States $u Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California92093, United States
- 700 1_
- $a O'Donoghue, Anthony J $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
- 700 1_
- $a Payne, Richard J $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia $u Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW2006, Australia $1 https://orcid.org/0000000236189226
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 65, č. 4 (2022), s. 2956-2970
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34730959 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130530 $b ABA008
- 999 __
- $a ok $b bmc $g 1788856 $s 1162137
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 65 $c 4 $d 2956-2970 $e 20211103 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- GRA __
- $a U01 TW006634 $p FIC NIH HHS $2 United States
- LZP __
- $a Pubmed-20220425